Roxana S. Dronca MD
Professor of Oncology, Mayo Clinic College of Medicine and Science; Chair, Hematology/Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FloridaDr. Roxana S. Dronca is a consultant and Chair of the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Jacksonville, Florida. She serves as Director of the Mayo Clinic Comprehensive Cancer Center, Florida Cancer Programs, and she also serves as a member of the Florida Executive Operations Team.
Dr. Dronca’s research interests are in the field of tumor immunology, with a particular interest in malignant melanoma and genitourinary malignancies. Her goal is to understand the interaction of immune and endocrine systems in modulating the anti-tumor immune response, study the dynamics and mechanisms of systemic immune regulation in cancer, and develop innovative approaches to cancer therapy utilizing chemotherapy and immunotherapy agents administered in an individualized fashion. She is active in education and has provided mentorship to multiple residents, fellows and faculty, among others. She holds master's faculty privileges in Clinical and Translational Science at Mayo Clinic Graduate School of Biomedical Sciences.
Dr. Dronca is a member of the Alliance for Clinical Trials in Cancer and serves on the Alliance Immuno-Oncology Advisory Committee. She is also active in the American Society of Clinical Oncology, the Society for Immunotherapy of Cancer, and the Society of Urologic Oncology, where she is a member of the Clinical Trials Consortium. She has also served as a scientist reviewer and panel chair for the Department of Defense Congressionally Directed Medical Research Program.
Recent Contributions to PracticeUpdate:
- FDA Approves Yervoy to Reduce the Risk of Melanoma Recurrence Post Surgery
- FDA Approves Yervoy to Reduce the Risk of Melanoma Returning After Surgery
- ECC 2015 Recap: Melanoma Recommendations From Dr. Roxana Dronca
- Pembrolizumab vs Investigator-Choice Chemotherapy for Ipilimumab-Refractory Melanoma (KEYNOTE-002)
- Dabrafenib and Trametinib vs Dabrafenib and Placebo for Val600 BRAF-Mutant Melanoma
- Adjuvant Ipilimumab for High-Risk Melanoma: Pros and Cons
- Adjuvant Ipilimumab Improves Recurrence-Free Survival in High-Risk Stage III Melanoma
- Ipilimumab Plus Sargramostim in Metastatic Melanoma
- Keytruda Takes Aim at the PD-1/PD-L1 Pathway
- FDA Approves Keytruda for Advanced Melanoma: First PD-1 Blocking Drug to Receive Agency Approval